多索茶碱联合吸入用复方异丙托溴铵溶液治疗60例支气管哮喘急性发作的疗效和安全性

目的:观察多索茶碱联合吸入用复方异丙托溴铵溶液治疗60例支气管哮喘急性发作的疗效和安全性。方法:将某院收治的60例支气管哮喘急性发作患者以抛币法均分为2组,对照组和治疗组均30例。对照组给予吸入用复方异丙托溴铵溶液等常规疗法治疗,治疗组给予多索茶碱联合吸入用复方异丙托溴铵溶液进行治疗。对2组患者治疗前后的PaO₂、PaCO₂两种常见临床主要血气指标的进行统计分析,并对患者治疗前后肺功能分析情况进行分析。统计2组患者整体疗效评价情况及治疗后不良反应情况。结果:治疗前,2组患者PaO₂、PaCO₂、FEV1、FEV1/FVC和PEF等指标比较无明显差异(P>0.05),治疗后2组血气指标和肺功能指标均得到显著改善(P<0.05)。治疗后,治疗组患者的PaO₂指标明显高于对照组,且治疗组患者的PaCO₂指标明显低于对照组,FEV1、FEV1/FVC和PEF三种主要肺功能指标明显高于对照组(P均<0.05)。治疗组总有效率为93.33%明显高于对照组的76.66%(P<0.05)。治疗组发生胃肠道反应、神经系统亢奋和过敏反应等不良反应情况的患者例数明显少于对照组,差异有统计学意义(P<0.05)。结论:多索茶碱联合吸入用复方异丙托溴铵溶液可有效治疗支气管哮喘急性发作患者,显效迅速,不良反应少,安全性高。

Efficacy and safety of doxofylline combined with combivent against acute exacerbation of bronchial asthma in 60 patients

OBJECTIVE To observe efficacy and safety of doxofylline combined with combivent against acute exacerbation of bronchial asthma. METHODS Sixty patients with acute exacerbation of bronchial asthma were randomly divided into control group (30 cases) and treatment group (30 cases). Patients in control group were treated by combivent, while patients in treatment group were treated by doxofylline combined with combivent. PaO₂, PaCO₂ and lung functions before and after treatment were determined. Overall efficacy evaluation was performed, adverse reactions after treatment were counted and statistically analyzed. RESULTS PaO₂ and PaCO₂ of two groups had no obviously difference (P>0.05) before treatment, but improved significantly after treatment (P<0.05). After treatment, PaO₂ was higher and PaCO₂ was lower in treatment group than in control group (P<0.05). FEV1, FEV1/FVC and PEF of two groups before treatment had no obvious difference (P>0.05). FEV1, FEV1/FVC and PEF of treatment group were higher than those of control group after treatment (P<0.05). Incidence of gastrointestinal tract reaction, nervous system excitement, allergic reactions and other adverse reactions of treatment group were higher than those of control group (P<0.05). Total efficiency of treatment group (93.33%) was higher than that of control group (76.66%) (P<0.05). CONCLUSION Doxofylline combined with combivent can markedly and quickly treat acute exacerbation of bronchial asthma. It has fewer adverse reactions and is safer.